Managing erythropoietin hyporesponsiveness.
The anemia of chronic kidney disease is associated with cardiovascular disease, decreased quality of life, and mortality. The introduction of recombinant human erythropoietin (rHuEPO) has transformed the management of this condition. However, a significant proportion of patients fail to respond to even high doses of rHuEPO. Several factors have been implicated in the hyporesponsiveness to rHuEPO. Iron deficiency, whether absolute or functional, is considered the most important, and maintenance of adequate iron stores reduces rHuEPO requirements among patients on hemodialysis. However, traditional indices of iron that are currently utilized may not reflect iron stores accurately, and there is also increasing concern regarding the potential long-term toxicity of parenteral iron therapy. Infection and inflammation also influence the response to rHuEPO, both by disruption of iron metabolism and by eliciting the release of cytokines that inhibit erythropoiesis. Oxidative stress may contribute to rHuEPO hyporesponsiveness directly by promoting lipid peroxidation in cell membranes, leading to increased erythrocyte fragility and reduced life span and also through its strong association with inflammation. Severe hyperparathyroidism can lead to a reduced number of erythroid progenitor cells. Inadequate dialysis dose, aluminum overload, nutritional factors such as deficiencies of carnitine, vitamin B12, folic acid, and vitamin C can also reduce the efficacy of rHuEPO therapy. Hyporesponsiveness to rHuEPO presents a challenge to both diagnosis and management in an era where optimizing response to rHuEPO is critical both in limiting the burgeoning costs of anemia management and improving clinical outcomes in the dialysis population.
Division of Nephrology, Department of Medicine, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA.
Christina
C
Kwack
Vaidyanathapuram S
VS
Balakrishnan
D000535:Aluminum / Q000097:blood; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D001361:Avitaminosis / Q000150:complications; D002331:Carnitine / Q000172:deficiency; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications; D007249:Inflammation / Q000150:complications; D007676:Kidney Failure, Chronic / Q000628:therapy; D018384:Oxidative Stress; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D011994:Recombinant Proteins; D004921:Erythropoietin; D000535:Aluminum; D002331:Carnitine